Drug Trial Radar · NCT02653898
Malaria Elimination Pilot Study in Military Forces in Cambodia
Last checked: Nov 20, 2026Latest source record: Mar 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,050
Actual
Start
Jan 2016
Primary completion
Aug 2016
Study completion Dec 2021
Sponsor
- Lead sponsor
- Armed Forces Research Institute of Medical Sciences, ThailandGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- National Center for Parasitology, Entomology, and Malaria Control (CNM); Ministry of National Defense, Royal Cambodian Armed Forces Department of Health
- First posted
- Jan 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Antimalarial drug resistance has reached critical levels on the Thai-Cambodian border. Many have begun advocating for concerted malaria elimination efforts in Cambodia. However, there is currently no consensus on how malaria elimination is to be achieved with the tools available. In this study, the investigators will conduct operational research with the Royal Cambodian Armed Forces (RCAF) and National Malaria Center (CNM) to quantify the relative effectiveness of the two major interventional approaches - monthly malaria prophylaxis (MMP) or focused screening and treatment (FSAT) - in a head to-head comparison. In addition, the investigators will quantify the relative contribution of a recently advocated vector intervention for military personnel - the insecticide treated uniform (ITU) - in addition to other vector control measures currently employed by the RCAF. The investigators will employ the same permethrin insecticide self-application kits currently used by the US military. The investigators will estimate the cost effectiveness of each approach and attempt to define the best way forward for malaria elimination efforts in a critically important malaria reservoir in military population (and their dependents) who reside on the Thai-Cambodian border. The aim of the study is not only to conduct research to better define the best way forward in malaria elimination efforts in the high risk military populations, but to also build capacity within the RCAF to support and lead future elimination efforts in the most difficult-to-reach mobile populations.
Conditions
- Malaria
- Parasitic Diseases
Interventions
DHA-PIPDrug
Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
PrimaquineDrug
22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
Artesunate + MefloquineDrug
Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
Permethrin (Insecticide treated uniform)Drug
40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- The absolute risk reduction based on the proportion of subjects remaining malaria-free at the end of 6 months between the study arms as diagnosed by PCR-corrected malaria microscopyTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RCAF treatment facilities
Anlong Veaeng, Oddar Meancheay, Cambodia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.